Literature DB >> 17643877

Nanoparticles loaded with ferrocenyl tamoxifen derivatives for breast cancer treatment.

Anh Nguyen1, Véronique Marsaud, Céline Bouclier, Siden Top, Anne Vessieres, Pascal Pigeon, Ruxandra Gref, Philippe Legrand, Gérard Jaouen, Jack-Michel Renoir.   

Abstract

For the first time, two organometallic triphenylethylene compounds (Fc-diOH and DFO), with strong antiproliferative activity in breast cancer cells, but insoluble in biological fluids, were incorporated in two types of stealth nanoparticles (NP): PEG/PLA nanospheres (NS) and nanocapsules (NC). Their physicochemical parameters were measured (size, zeta potential, encapsulation and loading efficiency), and their biological activity was assessed. In vitro drug release after high dilution of loaded NPs was measured by estradiol binding competition in MELN cells. The influence of the encapsulated drugs on the cell cycle and apoptosis was studied by flow cytometry analyses. Notwithstanding potential drug adsorption at the NP surface, Fc-diOH and DFO were incorporated efficiently in NC and NS, which slowly released both compounds. They arrested the cell cycle in the S-phase and induced apoptosis, whose activity is increased by loaded NS. A decrease in their antiproliferative activity by the antioxidant alpha-tocopherol indicated that reactive oxygen species (ROS) may be involved. Therefore, nanosystems, containing for the first time a high load of anticancer organometallic triphenylethylenes, have been developed. Their small size and delayed drug release, combined with their enhanced apoptotic potential, are compatible with an increased persistence in the blood and a promising antitumour activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17643877     DOI: 10.1016/j.ijpharm.2007.06.033

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

Review 1.  Tumor ablation and nanotechnology.

Authors:  Rachel L Manthe; Susan P Foy; Nishanth Krishnamurthy; Blanka Sharma; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

2.  Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect.

Authors:  Ngoc Trinh Huynh; Marie Morille; Jerome Bejaud; Pierre Legras; Anne Vessieres; Gerard Jaouen; Jean-Pierre Benoit; Catherine Passirani
Journal:  Pharm Res       Date:  2011-06-21       Impact factor: 4.200

3.  Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft.

Authors:  Emilie Allard; Delphine Jarnet; Anne Vessières; Sandrine Vinchon-Petit; Gérard Jaouen; Jean-Pierre Benoit; Catherine Passirani
Journal:  Pharm Res       Date:  2009-11-12       Impact factor: 4.200

4.  Polymer-drug interactions in tyrosine-derived triblock copolymer nanospheres: a computational modeling approach.

Authors:  Aurora D Costache; Larisa Sheihet; Krishna Zaveri; Doyle D Knight; Joachim Kohn
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

Review 5.  Organometallic anticancer compounds.

Authors:  Gilles Gasser; Ingo Ott; Nils Metzler-Nolte
Journal:  J Med Chem       Date:  2010-11-15       Impact factor: 7.446

6.  Succinimido-Ferrocidiphenol Complexed with Cyclodextrins Inhibits Glioblastoma Tumor Growth In Vitro and In Vivo without Noticeable Adverse Toxicity.

Authors:  Feten Najlaoui; Benoit Busser; Germain Sotoing Taïwe; Pascal Pigeon; Nathalie Sturm; Diane Giovannini; Naziha Marrakchi; Ali Rhouma; Gérard Jaouen; Stéphane Gibaud; Michel De Waard
Journal:  Molecules       Date:  2022-07-21       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.